Alchemab Targets ‘List Of The Worst-Served Diseases’
Biotech Raises $82m In Series A Financing
In an exclusive interview, Alchemab CEO Alex Leech talks to In Vivo about the company’s method of identifying naturally occurring antibodies to target high unmet needs in oncology, neurodegeneration and infectious diseases.
You may also be interested in...
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
In this latest installment of the VC Playbook series, In Vivo sits down with SV Health Investors’s Houman Ashrafian. The managing partner outlines the group’s investment philosophy, today’s skill set for VC success, and expectations for the future of Britain’s biotech industry post-Brexit and post-pandemic.
A selection of articles you might have missed from April 2021, including exclusive interviews with industry leaders and a deeper dive into drug development and R&D.